论文部分内容阅读
我们过去的工作表明,口服~(13)C-美沙西汀后,呼出气中~(13)CO_2的排出因肝功能障碍而延迟。这种延迟有两个可能的原因,一是肝细胞氧化美沙西汀的能力降低,二是肝功能障碍导致的肠吸收美沙西汀变慢。为此,用GC-MS技术以同位素反稀释法测定了口服~(13)C-美沙西汀15分钟后,血清中该标记物的浓度。测定结果。肝硬化患者血清~(13)C-美沙西汀含量显著高于正常人。证明肠吸收不良对~(13)C-美沙西汀呼气试验的结果无明显干扰,~(13)CO_2的排出延缓主要反映肝功能障碍。此外,血清含量的测定本身也有反映肝功能障碍的作用。
Our past work shows that after oral administration of ~ (13) C-methacetin, exhaled ~ (13) CO 2 efflux is delayed by liver dysfunction. There are two possible reasons for this delay, one is the reduced capacity of hepatocytes to oxidize mexitin, and the other is the slower intestinal absorption of methacetin due to liver dysfunction. For this purpose, the concentration of this marker in serum was determined 15 minutes after oral administration of ~ (13) C-methacetin by reverse-phase isotope dilution using GC-MS. The measurement results. The level of serum ~ (13) C-methacetin in patients with cirrhosis was significantly higher than that in normal people. Proved that malabsorption of ~ (13) C-methacetin breath test no significant interference, ~ (13) CO 2 of the discharge delay mainly reflects liver dysfunction. In addition, the determination of serum content itself also reflects the role of liver dysfunction.